Systematic review of the cost-effectiveness of the vaccination against HPV in Brazil

References

• Cancer. IAfRo. Globocan 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. France: World Heath Organization; 2012. [cited 2013.]. Available from: http://globocan.iarc.fr/
   Google Scholar
• Ministry. BH. Brazil. Health Ministry. Cancer incidence in Brazil—Estimate 2014. Rio de Janeiro.2014. [cited 2014]. Available from: http://www.inca.gov.br/estimativa/2014/estimativa-24012014.pdf
   Google Scholar
• Campos SS. Estudos sobre o câncer nos índios do Brasil. Revista Brasileira de Cancerologia 1961; 2:33-50.
   Google Scholar
• Thuler LCS, Zardo LM, Zeferino LC. Perfil dos laboratórios de citopatologia do Sistema Único de Saúde. J Bras Patol Med Lab 2007; 43:103-14; http://dx.doi.org/10.1590/S1676-24442007000200006
   Google Scholar
• Vale DBAP, Morais SS, Pimenta AL, Zeferino LC. Avaliação do rastreamento do câncer do colo do útero na Estratégia Saúde da Família no Município de Amparo, São Paulo, Brasil. Cad Saúde Pública 2010; 26:383-90; http://dx.doi.org/10.1590/S0102-311X2010000200017
   PubMed Web of Science ®Google Scholar
• Santos RS, Melo ECP, Santos KM. Análise espacial dos indicadores pactuados para o rastreamento do câncer do colo do útero no Brasil. Texto Contexto Enferm 2012; 21:800-10
   Google Scholar
• Zeferino LC. [The challenge of reducing mortality due to cervical cancer]. Rev Bras Ginecol Obstet 2008; 30(5):213-5; PMID:19142494
   PubMedGoogle Scholar
• Sarian LO, Derchain SF, Bastos JF. [Diagnostic methods for cervical cancer screening]. Rev Bras Ginecol Obstet 2010; 32(8):363-7; PMID:21180871
   PubMedGoogle Scholar
• Caetano R, Vianna CMdM, Thuler LCS, Girianelli VR. Cost-effectiveness of the early diagnosis of cervical cancer in Brazil. Rev Sade Coletiva 2006; 16:99-118
   Google Scholar
• Hutubessy R, Henao AM, Namgyal P, Moorthy V, Hombach J. Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal. BMC Med 2011; 9:55; PMID:21569407; http://dx.doi.org/10.1186/1741-7015-9-55
   PubMed Web of Science ®Google Scholar
• Jit M, Demarteau N, Elbasha E, Ginsberg G, Kim J, Praditsitthikorn N, et al. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Med 2011; 9:54; PMID:21569406; http://dx.doi.org/10.1186/1741-7015-9-54
   PubMed Web of Science ®Google Scholar
• Barnabas RV, Kulasingam SL. Economic evaluations of human papillomavirus vaccines. Expert Rev Pharmacoecon Outcomes Res 2007; 7(3):251-67; PMID:20528312; http://dx.doi.org/10.1586/14737167.7.3.251
   PubMedGoogle Scholar
• Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O'Shea MK, et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007; 25(33):6257-70; PMID:17606315; http://dx.doi.org/10.1016/j.vaccine.2007.05.058
   PubMed Web of Science ®Google Scholar
• Colantonio L, Gomez JA, Demarteau N, Standaert B, Pichon-Riviere A, Augustovski F. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine 2009; 27(40):5519-29; PMID:19616499; http://dx.doi.org/10.1016/j.vaccine.2009.06.097
   PubMed Web of Science ®Google Scholar
• Kawai K, de Araujo GT, Fonseca M, Pillsbury M, Singhal PK. Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model. BMC Infect Dis 2012; 12:250; PMID:23046886; http://dx.doi.org/10.1186/1471-2334-12-250
   PubMed Web of Science ®Google Scholar
• Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007; 97(9):1322-8; PMID:17923869; http://dx.doi.org/10.1038/sj.bjc.6604023
   PubMed Web of Science ®Google Scholar
• Vanni T, Mendes Luz P, Foss A, Mesa-Frias M, Legood R. Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: a dynamic individual-based approach. Vaccine 2012; 30(32):4866-71; PMID:22652405; http://dx.doi.org/10.1016/j.vaccine.2012.04.087
   PubMed Web of Science ®Google Scholar
• Fonseca AJ, Ferreira LC, Neto GB. Cost-effectiveness of the vaccine against human papillomavirus in the Brazilian Amazon region. Rev Assoc Med Bras 2013; 59(5):442-51; PMID:24041909; http://dx.doi.org/10.1016/j.ramb.2013.03.004
   PubMed Web of Science ®Google Scholar
• Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008; 26(32):4080-93; PMID:18550229; http://dx.doi.org/10.1016/j.vaccine.2008.04.053
   PubMed Web of Science ®Google Scholar
• Dee A, Howell F. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health 2010; 20(2):213-9; PMID:19864366; http://dx.doi.org/10.1093/eurpub/ckp141
   PubMed Web of Science ®Google Scholar
• Szucs TD, Largeron N, Dedes KJ, Rafia R, Benard S. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 2008; 24(5):1473-83; PMID:18413014; http://dx.doi.org/10.1185/030079908X297826
   PubMed Web of Science ®Google Scholar
• Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff Resour Alloc 2008; 6:4; PMID:18279515; http://dx.doi.org/10.1186/1478-7547-6-4
   PubMedGoogle Scholar
• Torvinen S, Nieminen P, Lehtinen M, Paavonen J, Demarteau N, Hahl J. Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise. J Med Econ 2010; 13(2):284-94; PMID:20482244; http://dx.doi.org/10.3111/13696998.2010.485951
   PubMedGoogle Scholar
• Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359(8):821-32; PMID:18716299; http://dx.doi.org/10.1056/NEJMsa0707052
   PubMed Web of Science ®Google Scholar
• de Kok IM, van Ballegooijen M, Habbema JD. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2009; 101(15):1083-92; PMID:19571256; http://dx.doi.org/10.1093/jnci/djp183
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010; 28(42):6858-67; PMID:20713101; http://dx.doi.org/10.1016/j.vaccine.2010.08.030
   PubMed Web of Science ®Google Scholar
• Kane MA. Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine. Gynecol Oncol 2010; 117(2 Suppl):S32-5; PMID:20129654; http://dx.doi.org/10.1016/j.ygyno.2010.01.029
   PubMed Web of Science ®Google Scholar